Eli Lilly and Company, Gilead Sciences, Vertex Pharmaceuticals, Novo Nordisk A/S, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are public equity shares of companies engaged in the research, development, production and marketing of prescription drugs, over-the-counter medications and other therapeutic treatments. Their performance is often driven by factors such as clinical trial results, regulatory approvals or setbacks, patent expirations and shifts in healthcare policy and demand. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded down $15.71 on Friday, reaching $625.15. 14,089,857 shares of the company's stock were exchanged, compared to its average volume of 4,833,475. The firm has a market capitalization of $592.48 billion, a price-to-earnings ratio of 40.86, a PEG ratio of 0.91 and a beta of 0.44. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The business's 50-day moving average is $774.10 and its two-hundred day moving average is $798.80. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.
Read Our Latest Research Report on LLY
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of NASDAQ:GILD traded up $9.13 on Friday, reaching $119.41. 13,112,190 shares of the company's stock were exchanged, compared to its average volume of 5,807,634. The firm has a market capitalization of $148.54 billion, a price-to-earnings ratio of 23.79, a PEG ratio of 0.70 and a beta of 0.33. Gilead Sciences has a fifty-two week low of $72.43 and a fifty-two week high of $121.38. The business's 50-day moving average is $110.93 and its two-hundred day moving average is $107.43. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.
Read Our Latest Research Report on GILD
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of VRTX stock traded down $9.09 during trading hours on Friday, reaching $366.54. The stock had a trading volume of 3,679,339 shares, compared to its average volume of 1,989,627. Vertex Pharmaceuticals has a twelve month low of $364.66 and a twelve month high of $519.88. The firm has a 50-day simple moving average of $450.77 and a 200-day simple moving average of $465.51. The firm has a market capitalization of $93.98 billion, a PE ratio of 26.20 and a beta of 0.44.
Read Our Latest Research Report on VRTX
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NVO stock traded up $2.30 during trading hours on Friday, reaching $51.06. The stock had a trading volume of 23,312,357 shares, compared to its average volume of 23,928,642. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $139.74. The firm has a 50-day simple moving average of $67.14 and a 200-day simple moving average of $71.60. The firm has a market capitalization of $227.98 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63.
Read Our Latest Research Report on NVO
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of PFE stock traded up $0.34 during trading hours on Friday, reaching $24.57. The stock had a trading volume of 36,356,648 shares, compared to its average volume of 46,490,120. The firm has a 50-day simple moving average of $24.44 and a 200-day simple moving average of $24.50. The firm has a market capitalization of $139.69 billion, a PE ratio of 13.07, a price-to-earnings-growth ratio of 0.87 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.96. Pfizer has a twelve month low of $20.92 and a twelve month high of $30.43.
Read Our Latest Research Report on PFE
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
